Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.

ABSTRACT:

Objective

The second-generation antipsychotics are associated with metabolic abnormalities in patients with schizophrenia. Elderly patients with Alzheimer's disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects.

Method

The authors assessed 186 male and 235 female Alzheimer's disease outpatients from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) for changes in weight, waist circumference, blood pressure, fasting glucose, and lipids in relation to duration of second-generation antipsychotic use (i.e., olanzapine, quetiapine, and risperidone) throughout the 36-week trial, using logistic regression and mixed-effects models.

Results

Women showed significant weight

SUBMITTER: Zheng L 

PROVIDER: S-EPMC2891018 | biostudies-literature | 2009 May

REPOSITORIES: biostudies-literature